PF 07921585
Alternative Names: PF-07921585Latest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antineoplastics; Proteins
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (IV) (NCT06580938)
- 01 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (SC) (NCT06580938)
- 01 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA (IV) (NCT06580938)